Human African trypanosomiasis (HAT) or sleeping sickness is a parasitic disease, acquired by the bite of an infected tsetse fly. In non-endemic countries HAT is rare, and therefore the diagnosis may be delayed leading to potentially fatal consequences. In this article the clinical presentation, diagnosis and treatment of the two forms of HAT are outlined. Rhodesiense HAT is an acute illness that presents in tourists who have recently visited game parks in Eastern or Southern Africa, whereas Gambiense HAT has a more chronic clinical course, in individuals from West or Central Africa.

Introduction
Human African trypanosomiasis (HAT) or sleeping sickness is a disease transmitted by the tsetse fly, affecting the poorest communities in sub-Saharan Africa. HAT is rare in non-endemic countries, and is therefore often not considered as the diagnosis, which can lead to serious complications, including death.

This article is aimed at clinicians in non-endemic countries. It provides a broad overview of HAT, focusing particularly on presentation and diagnosis (a useful learning tool can be found at www.braininfectionsuk.org/neuroid_elearning/).

Epidemiology
HAT is endemic to 36 African countries, occurring in highly specific foci in rural areas. Between 2000-2010, 94 HAT cases were reported in non-endemic countries (Fig 1). Specifically, 72% of cases were due to the East-African form (Rhodesiense HAT), and 28% due to the West-African form (Gambiense HAT), which is a reversal of the proportions attributable to each species in endemic areas. Rhodesiense HAT classically occurs in tourists visiting the game parks of East and South Africa. Multiple individuals visiting the same area have been affected. In Gambiense HAT the main risk groups are migrants or long-term travellers. A detailed review of non-endemic cases of HAT over the last 20 years was performed by Migchelsen SJ et al in 2011.

Clinical features
Classically, Gambiense HAT is a chronic infection lasting years, whereas Rhodesiense HAT is an acute presentation, progressing within weeks. In both diseases, clinical symptoms appear in two progressive stages; stage 1 (haemolymphatic stage) and stage 2 (meningoencephalitic stage), which occurs following entry of parasites into the central nervous system (CNS). Traditionally HAT is considered fatal without treatment. However, there is increasing recognition that HAT is a diverse condition; the chronology of symptoms can vary widely and not all cases are fatal. This variability in presentation depends on multiple factors; including the specific parasite strain and the background of the host affected (travellers or migrants).

Rhodesiense HAT
For the most part, Rhodesiense HAT presents as an acute febrile illness in travellers, with an incubation period of a few days to three weeks. Initial symptoms include high fever, headache, gastrointestinal complaints (nausea, vomiting and jaundice), lymphadenopathy and headache. Dermatological manifestations may be helpful discriminating features (Box 1). As the illness progresses, patients may develop cardiac features which include myopericarditis and arrhythmias, as well as occasional neurological symptoms. In severe cases, patients develop signs of multiorgan failure following peaks of trypanosomal parasitaemia.

Gambiense HAT
Migrants
African migrants present with symptoms of Gambiense HAT many years after moving from the endemic area. Most cases present within seven years, but case reports show presentation 29 years after visiting an endemic area. The clinical presentation is characterised by low-grade fever and neuropsychiatric symptoms that can last months. Neurological features include a typical sleep disorder, motor and sensory disturbances, abnormal reflexes and psychiatric symptoms. The sleep disorder consists of reversal of the normal sleep–wake cycle and uncontrollable episodes of sleep. Motor disturbances

Authors: Darshan Sudarshi* and Mike Brown*
include weakness, tremor and abnormal gait. Psychiatric features include low mood, hallucinations, delirium, anxiety and irritability. In the later stages if untreated, generalised meningoencephalitis leads to coma and death. Due to the long incubation period and indolent course, Gambiense HAT is often misdiagnosed initially\(^2\) (Box 2).

**Travellers**

In contrast to migrants, most travellers present with an acute febrile illness similar to Rhodesiense HAT with an incubation period of 1 month.\(^9\)

**Laboratory results**

In both forms of HAT, blood tests may show anaemia and thrombocytopenia, impaired kidney and liver function, as well as raised inflammatory markers. HAT causes polyclonal gammaglobulinemia leading to markedly raised IgM levels\(^10\) which can lead to many cross-reacting antibodies\(^7,11\) (Box 2).

**Diagnosis and staging**

**Visualisation of the parasite**

Definitive diagnosis of HAT requires microscopic demonstration of the parasite in peripheral blood, lymph node, chancre aspirate or cerebrospinal fluid (CSF). In the vast majority of cases, Rhodesiense HAT is diagnosed by thick blood film.\(^12\) Gambiense HAT is more challenging to diagnose in the blood (Box 3), so specimens from multiple sites should be taken. Serology (and polymerase chain reaction (PCR) if available) is useful when visualisation techniques have failed.

---

**Box 1. Dermatological features of Rhodesiense HAT.**

In the initial stages, Rhodesiense HAT can present in a similar fashion to malaria, rickettsial infections and other tropical infections. Specific dermatological features can be useful clues of when to suspect this rare disease.

- **Tsetse fly bite:** many travellers will recall being bitten by tsetse flies, which may raise the level of suspicion.
- **Chancre:** a trypanosomal chancre consists of a tender, purplish, indurated area of erythema. It typically appears after 1 week of the tsetse fly bite at the same site and is a highly specific sign estimated to occur in 84% of travellers with Rhodesiense HAT\(^3\) (Fig 2).
- **Trypanosomal rash:** after the first febrile episode, patients may occasionally develop a non-itchy, transient maculopapular rash on the torso.

\(^{115}\) CME Tropical medicine © Royal College of Physicians 2015. All rights reserved.

---

**Fig 1. HAT cases diagnosed in non-endemic countries (2000–2010).** HAT cases reported in non-endemic countries between 2000 and 2010 are illustrated on the map. Squares represent the place of diagnosis; triangles indicate the probable place of infection. Cases were compiled using a combination of published articles as well as those reported directly to the World Health Organization. Reproduced with permission.\(^1\) HAT = human African trypanosomiasis.

---

**Fig 2. Trypanosomal chancre on shoulder of patient.** Reproduced with permission of Hospital Tropical Diseases.\(^5\)
Staging

Determination of CNS involvement is important to tailor therapy. Evidence of this is defined by either trypanosomes seen in CSF or increased CNS lymphocyte counts (>5 cells/µl)\(^1\)\(^3\). In Rhodesiense HAT, suramin therapy should be commenced immediately and lumbar puncture should be deferred until blood parasitaemia has declined.\(^6\)

Treatment and follow up

There are five licensed drugs for HAT, which are stocked in specialist tropical medicine centres in several non-endemic countries.\(^1\) If treatment is not readily available, drugs can be delivered free of charge from the World Health Organization (WHO) within 24–48 hours. Treatment depends on the type and stage of HAT\(^1\)\(^3\) (Table 1). All drugs are highly toxic and advice should be taken from tropical medicine specialists. Follow up for all patients is essential to ensure relapse does not occur.

Preventative measures

Travellers visiting HAT endemic areas should be advised to take general protective precautions. The tsetse fly is active...
during daytime and is particularly attracted by motion and blue and black surfaces. Therefore, risk of exposure can be reduced by wearing full-length clothing with impregnation of permethrin, avoiding dark colours and regular application of skin repellent. A detailed report on the control and surveillance of HAT was published by the WHO in 2013.14

References

Address for correspondence: Dr D Sudarshi, Hospital for Tropical Diseases, Capper Street, London WC1E 6JB, UK.
Email: darsh@doctors.org.uk

Table 1. Summary of HAT drugs by type and disease stage.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Rhodesiense HAT</th>
<th>Gambiense HAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Suramin IV – test dose then 5 doses every 7 days.</td>
<td>Pentamidine IM – 7 days.</td>
</tr>
<tr>
<td></td>
<td>Side effects: early hypersensitivity reaction (urticaria and hypotension), albuminuria, haematuria and peripheral neuropathy.</td>
<td>Side effects: hypoglycaemia, hypotension, injection site pain and GI disturbance.</td>
</tr>
<tr>
<td>2</td>
<td>Melarsoprol IV – 10 days.</td>
<td>First line therapy: nifurtimox–elfornithine combination therapy.</td>
</tr>
<tr>
<td></td>
<td>Side effects: post-treatment reactive encephalopathy occurs in 10–15% of patients and is fatal in half of these, peripheral neuropathy, skin reactions and thrombophlebitis.</td>
<td>Eflornithine IV – 7 days and nifurtimox PO – 10 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Side effects: GI disturbance, anaemia, thrombocytopenia and convulsions.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second line therapies: eflornithine IV – 14 days or melarsoprol IV – 10 days.</td>
</tr>
</tbody>
</table>

GI = gastrointestinal; HAT = human African trypanosomiasis.